MCID: CRN020
MIFTS: 39

Coronary Restenosis

Categories: Cardiovascular diseases

Aliases & Classifications for Coronary Restenosis

MalaCards integrated aliases for Coronary Restenosis:

Name: Coronary Restenosis 12 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4247
MeSH 44 D023903
UMLS 73 C0948480

Summaries for Coronary Restenosis

MalaCards based summary : Coronary Restenosis is related to angina pectoris and acute myocardial infarction. An important gene associated with Coronary Restenosis is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Toxoplasmosis and Complement and coagulation cascades. The drugs Celecoxib and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and testes, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Coronary Restenosis

Diseases related to Coronary Restenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 angina pectoris 30.4 ACE SERPINC1
2 acute myocardial infarction 29.9 ACE PLAT SERPINC1
3 coronary artery anomaly 29.5 ACE CETP PLAT
4 myocardial infarction 29.3 ACE CETP PLAT SERPINC1
5 arteries, anomalies of 28.9 ACE CETP PLAT SERPINC1
6 renal artery obstruction 10.5 ACE SERPINC1
7 aortic atherosclerosis 10.5 ACE CETP
8 ischemic optic neuropathy 10.4 ACE SERPINC1
9 intermittent claudication 10.4 ACE SERPINC1
10 coronary stenosis 10.4 ACE CETP
11 nonarteritic anterior ischemic optic neuropathy 10.3 ACE SERPINC1
12 fibrinolytic defect 10.3 PLAT SERPINC1
13 hemorrhage, intracerebral 10.3 ACE PLAT
14 argentine hemorrhagic fever 10.3 PLAT SERPINC1
15 platelet aggregation, spontaneous 10.3 PLAT SERPINC1
16 intracranial embolism 10.3 PLAT SERPINC1
17 pulmonary edema 10.3 ACE SERPINC1
18 posterior myocardial infarction 10.3 PLAT SERPINC1
19 encephalopathy, familial, with neuroserpin inclusion bodies 10.3 PLAT SERPINC1
20 marantic endocarditis 10.3 PLAT SERPINC1
21 thrombophlebitis 10.3 PLAT SERPINC1
22 coronary thrombosis 10.3 PLAT SERPINC1
23 coronary heart disease 1 10.3 ACE CETP
24 dysfibrinogenemia 10.2 PLAT SERPINC1
25 endotheliitis 10.2
26 hepatic veno-occlusive disease 10.2 PLAT SERPINC1
27 vein disease 10.2 PLAT SERPINC1
28 thrombophilia due to activated protein c resistance 10.2 PLAT SERPINC1
29 chronic venous insufficiency 10.1 ITGA4 PLAT
30 thrombophilia due to thrombin defect 10.1 PLAT SERPINC1
31 venous insufficiency 10.1 ITGA4 PLAT
32 disseminated intravascular coagulation 10.0 PLAT SERPINC1
33 toxic shock syndrome 10.0 SERPINC1 TLR2
34 antiphospholipid syndrome 10.0 PLAT SERPINC1
35 lipid metabolism disorder 10.0 ACE CETP
36 intermediate coronary syndrome 9.9 ACE PLAT SERPINC1
37 peripheral vascular disease 9.9 ACE PLAT SERPINC1
38 diabetes mellitus, noninsulin-dependent 9.9
39 diabetes mellitus 9.9
40 stroke, ischemic 9.9 ACE PLAT SERPINC1
41 pulmonary embolism 9.8 PLAT SERPINC1
42 mooren's ulcer 9.8 ITGA4 ITGB2
43 endocarditis 9.8 PLAT SERPINC1 TLR2
44 autoimmune disease 9.8
45 aging 9.8
46 autoimmune disease 1 9.8
47 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
48 ischemic heart disease 9.8
49 heart disease 9.8
50 cytomegalovirus infection 9.8

Graphical network of the top 20 diseases related to Coronary Restenosis:



Diseases related to Coronary Restenosis

Symptoms & Phenotypes for Coronary Restenosis

MGI Mouse Phenotypes related to Coronary Restenosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.63 ACE ITGA4 ITGB2 PLAT SERPINC1 TLR2
2 hematopoietic system MP:0005397 9.43 TLR2 ACE ITGA4 ITGB2 PLAT SERPINC1
3 immune system MP:0005387 9.1 TLR2 ACE ITGA4 ITGB2 PLAT SERPINC1

Drugs & Therapeutics for Coronary Restenosis

Drugs for Coronary Restenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
5
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 33069-62-4 36314
6
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
7
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
10
Probucol Approved, Investigational Phase 4 23288-49-5 4912
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
13
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
14
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
15
Polyestradiol phosphate Approved Phase 4 28014-46-2
16 Epoetin alfa Phase 4 113427-24-0
17 Analgesics Phase 4
18 Albumin-Bound Paclitaxel Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Cyclooxygenase 2 Inhibitors Phase 4
20 Hematinics Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Angiogenesis Inhibitors Phase 4
24 Angiogenesis Modulating Agents Phase 4
25 Peripheral Nervous System Agents Phase 4
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Platelet Aggregation Inhibitors Phase 4
29 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4
34 Antirheumatic Agents Phase 4
35 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Prasugrel hydrochloride Phase 4 389574-19-0
38 Fibrinolytic Agents Phase 4,Not Applicable
39 Neurotransmitter Agents Phase 4
40 Technetium Tc 99m Sestamibi Phase 4
41 Hormone Antagonists Phase 4
42 Hormones Phase 4
43 Angiotensin II Type 1 Receptor Blockers Phase 4
44 Angiotensin Receptor Antagonists Phase 4
45 Angiotensinogen Phase 4
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
47 Estradiol 17 beta-cypionate Phase 4
48 Hypolipidemic Agents Phase 4,Not Applicable
49 Estradiol 3-benzoate Phase 4
50 Estrogens Phase 4

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents Unknown status NCT00714545 Phase 4
2 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
3 Anti-Restenosis After AMI by Erythropoietin Unknown status NCT00423020 Phase 4 Erythropoietin
4 Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation Unknown status NCT01638078 Phase 4 Thalidomide;Placebo
5 Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) Unknown status NCT00963781 Phase 4 Reduced duration (6 months) DAPT
6 Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis Completed NCT00598533 Phase 4
7 Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents Completed NCT00627900 Phase 4
8 Oral Sirolimus for In-Stent Restenosis Completed NCT00859183 Phase 4 Sirolimus;Sirolimus;Placebo
9 Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT) Completed NCT00752362 Phase 4
10 Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty Completed NCT00162357 Phase 4 Technetium Tc99m Sestamibi
11 The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis Completed NCT00332397 Phase 4
12 Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents Completed NCT00598715 Phase 4
13 Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents Completed NCT00552669 Phase 4 Oral sirolimus
14 Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE) Completed NCT00402636 Phase 4
15 Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis (ISAR-TEST-3) Completed NCT00350454 Phase 4
16 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study) Completed NCT01171820 Phase 4
17 SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe Completed NCT00402272 Phase 4
18 Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes Completed NCT00599885 Phase 4 telmisartan;valsartan
19 EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Completed NCT00531011 Phase 4
20 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente Completed NCT01066650 Phase 4
21 XIENCE V: SPIRIT WOMEN Sub-study Completed NCT01182428 Phase 4
22 XIENCE V: SPIRIT WOMEN Completed NCT00496938 Phase 4
23 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population Completed NCT01331707 Phase 4
24 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed NCT01178268 Phase 4
25 XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort Completed NCT01106534 Phase 4 placebo + aspirin;clopidogrel + aspirin OR prasugrel + aspirin
26 Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions Completed NCT00911976 Phase 4
27 Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions Active, not recruiting NCT02300454 Phase 4
28 Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis Terminated NCT01967199 Phase 4
29 Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation Unknown status NCT00426049 Phase 3 Everolimus
30 PIoglitazone for PrEvention of Restenosis in Diabetic Patients Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
31 Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period Completed NCT00882219 Phase 3
32 Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis Completed NCT00287573 Phase 2, Phase 3
33 A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels. Completed NCT00055510 Phase 2, Phase 3 BO-653
34 SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System Completed NCT00180310 Phase 3
35 Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries Completed NCT00148356 Phase 2, Phase 3
36 BioFreedom FIM Clinical Trial. Completed NCT01172119 Phase 2, Phase 3
37 SPIRIT PRIME Clinical Trial Completed NCT00916370 Phase 3
38 Limus Eluted From A Durable Versus ERodable Stent Coating Completed NCT00389220 Phase 3
39 SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System Completed NCT00307047 Phase 3
40 The SOS (Stenting Of Saphenous Vein Grafts) Trial Completed NCT00247208 Phase 3
41 SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) Completed NCT00180479 Phase 3
42 Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon Recruiting NCT03242096 Phase 2, Phase 3
43 ABSORB Clinical Investigation, Cohort B Unknown status NCT00856856 Phase 1, Phase 2
44 The Effects of Bindarit in Preventing Stent Restenosis Completed NCT01269242 Phase 2 bindarit;bindarit;placebo
45 Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II) Completed NCT00409981 Phase 1, Phase 2
46 Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis Completed NCT00124943 Phase 1, Phase 2 Nanoparticle Paclitaxel
47 Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR I) Completed NCT00106587 Phase 1, Phase 2
48 OCT Evaluation of Healing of COMBO Stent Completed NCT01274234 Phase 1, Phase 2
49 Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries Completed NCT00248066 Phase 2 RESTEN-MP
50 Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries Completed NCT00140101 Phase 2

Search NIH Clinical Center for Coronary Restenosis

Cochrane evidence based reviews: coronary restenosis

Genetic Tests for Coronary Restenosis

Anatomical Context for Coronary Restenosis

MalaCards organs/tissues related to Coronary Restenosis:

41
Endothelial, Liver, Testes, Smooth Muscle, Monocytes, Adipocyte, Heart

Publications for Coronary Restenosis

Articles related to Coronary Restenosis:

(show top 50) (show all 177)
# Title Authors Year
1
Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease. ( 29716394 )
2018
2
Third generation dual-source CT enables accurate diagnosis of coronary restenosis in all size stents with low radiation dose and preserved image quality. ( 29349698 )
2018
3
Anti-Inflammatory Effect of Gallic Acid-Eluting Stent in a Porcine Coronary Restenosis Model. ( 29844643 )
2018
4
Associations between endothelial progenitor cells, clinical characteristics and coronary restenosis in patients undergoing percutaneous coronary artery intervention. ( 29739448 )
2018
5
Effect of Stents Coated with Artemisinin or Dihydroartemisinin in a Porcine Coronary Restenosis Model. ( 28154599 )
2017
6
Recurrent coronary restenosis treated with Chinese medicine: A case report. ( 28861805 )
2017
7
The Control of Drug Release and Vascular Endothelialization after Hyaluronic Acid-Coated Paclitaxel Multi-Layer Coating Stent Implantation in Porcine Coronary Restenosis Model. ( 28154600 )
2017
8
Drug- and Gene-eluting Stents for Preventing Coronary Restenosis. ( 28184335 )
2017
9
Five-year follow-up of the endothelial progenitor cell capturing stent versus the paxlitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis. ( 28868810 )
2017
10
A novel polymer-free drug-eluting stent coated with everolimus using nitrogen-doped titanium dioxide film deposition in a porcine coronary restenosis model. ( 27505330 )
2016
11
Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial). ( 27634828 )
2016
12
Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model. ( 27976797 )
2016
13
Impact of Angiographic Result After Predilatation on Outcome After Drug-Coated Balloon Treatment of In-Stent Coronary Restenosis. ( 27634028 )
2016
14
Stent linker effect in a porcine coronary restenosis model. ( 26318568 )
2016
15
Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model. ( 26886814 )
2016
16
TCT-837 Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model. ( 27970228 )
2016
17
Effect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model. ( 25810732 )
2015
18
Controlled Slow-Release Drug-Eluting Stents for the Prevention of Coronary Restenosis: Recent Progress and Future Prospects. ( 26011753 )
2015
19
Association of ACE insertion or deletion polymorphisms with the risk of coronary restenosis after percutaneous coronary intervention: A meta-analysis. ( 26195267 )
2015
20
Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation. ( 26337618 )
2015
21
Pharmacological inhibition of coronary restenosis: systemic and local approaches. ( 25145263 )
2014
22
Effect of polymer-free TiO2 stent coated with abciximab or alpha lipoic acid in porcine coronary restenosis model. ( 24852847 )
2014
23
A micro RNA-146a polymorphism is associated with coronary restenosis. ( 25053223 )
2014
24
Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. ( 24465275 )
2014
25
Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model. ( 24363750 )
2013
26
Two-dimensional fluorescence in-gel electrophoresis of coronary restenosis tissues in minipigs: increased adipocyte fatty acid binding protein induces reactive oxygen species-mediated growth and migration in smooth muscle cells. ( 23372061 )
2013
27
Pathway analysis using genome-wide association study data for coronary restenosis - a potential role for the PARVB gene. ( 23950981 )
2013
28
Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: evidence from 33 cohort studies. ( 24098690 )
2013
29
Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model. ( 23678471 )
2013
30
Influence of the Angiotensin converting enzyme insertion or deletion genetic variant and coronary restenosis risk: evidence based on 11,193 subjects. ( 24349507 )
2013
31
Regular exercise training reduces coronary restenosis after percutaneous coronary intervention in patients with acute myocardial infarction. ( 22795710 )
2013
32
Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention. ( 22454659 )
2012
33
Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study. ( 22879966 )
2012
34
Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. ( 21301785 )
2011
35
Effects of ramiprilat-coated stents on neointimal hyperplasia, inflammation, and arterial healing in a porcine coronary restenosis model. ( 22022329 )
2011
36
Coronary restenosis and contact allergy to stent material. ( 21608294 )
2011
37
Effect of a dual drug-coated stent with abciximab and alpha-lipoic Acid in a porcine coronary restenosis model. ( 21731564 )
2011
38
The association between epicardial fat thickness in echocardiography and coronary restenosis in drug eluting stents. ( 22577439 )
2011
39
Drug-eluting stent as an option for intractable in-stent coronary restenosis. ( 22194765 )
2011
40
Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. ( 20834185 )
2010
41
Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. ( 19933225 )
2010
42
Right-sided chest leads in exercise testing for detection of coronary restenosis. ( 20162735 )
2010
43
Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model. ( 20436707 )
2010
44
Lack of association between the cholesteryl ester transfer protein gene--TaqIB polymorphism and coronary restenosis following percutaneous transluminal coronary angioplasty and stenting: a pilot study. ( 19815603 )
2010
45
Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. ( 20226618 )
2010
46
Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. ( 19962471 )
2009
47
Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era. ( 19712016 )
2009
48
A simple ECG marker for the detection of coronary restenosis after successful coronary angioplasty. ( 19834270 )
2009
49
Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. ( 19280084 )
2009
50
Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. ( 19592388 )
2009

Variations for Coronary Restenosis

Expression for Coronary Restenosis

Search GEO for disease gene expression data for Coronary Restenosis.

Pathways for Coronary Restenosis

GO Terms for Coronary Restenosis

Cellular components related to Coronary Restenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.63 ACE CETP ITGA4 ITGB2 PLAT SERPINC1
2 integrin complex GO:0008305 8.96 ITGA4 ITGB2
3 cell surface GO:0009986 8.92 ITGA4 ITGB2 PLAT TLR2

Biological processes related to Coronary Restenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endodermal cell differentiation GO:0035987 9.26 ITGA4 ITGB2
2 leukocyte cell-cell adhesion GO:0007159 9.16 ITGA4 ITGB2
3 receptor clustering GO:0043113 8.96 ITGA4 ITGB2
4 heterotypic cell-cell adhesion GO:0034113 8.62 ITGA4 ITGB2

Molecular functions related to Coronary Restenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion molecule binding GO:0050839 8.62 ITGA4 ITGB2

Sources for Coronary Restenosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....